Human Vaccines & Immunotherapeutics (Apr 2017)

Invasive pneumococcal disease: From a tertiary care hospital in the post-vaccine era

  • Sevgen Tanır Basaranoglu,
  • Eda Karadag Oncel,
  • Kubra Aykac,
  • Yasemin Ozsurekci,
  • Ali Bülent Cengiz,
  • Ates Kara,
  • Mehmet Ceyhan

DOI
https://doi.org/10.1080/21645515.2016.1256519
Journal volume & issue
Vol. 13, no. 4
pp. 962 – 964

Abstract

Read online

A breakthrough infection occurring with 13-valent pneumococcal conjugate vaccine (PCV13) in Turkey are previously described. A breakthrough infection is defined as IPD in a child who had received ≥ 1 PCV-7 or PCV-13 and for which the pneumococcal isolate was a vaccine serotype. During one year period, among 6 patients with invasive pneumococcal infection, 2 patients were considered to have a vaccine failure with serotype 19F. Antibiotic resistance results were remarkable; macrolide resistance were observed in all strains except one, and high and intermediate penicillin resistance were determined in 2 strains.

Keywords